Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2012

01-03-2012 | Research Articles

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation

Authors: Elizabeth Charytonowicz, Igor Matushansky, Josep Domingo-Doménech, Mireia Castillo-Martín, Marc Ladanyi, Carlos Cordon-Cardo, Mel Ziman

Published in: Clinical and Translational Oncology | Issue 3/2012

Login to get access
Metadata
Title
PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation
Authors
Elizabeth Charytonowicz
Igor Matushansky
Josep Domingo-Doménech
Mireia Castillo-Martín
Marc Ladanyi
Carlos Cordon-Cardo
Mel Ziman
Publication date
01-03-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0784-4

Other articles of this Issue 3/2012

Clinical and Translational Oncology 3/2012 Go to the issue

Research Articles

Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers

Brief Research Article

Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain

Research Articles

Laryngeal cancer survival in Zaragoza (Spain): a population-based study

Research Articles

Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients

Educational Series / Blue Series

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Research Articles

Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits